Journal Article
. 2017 Jul;165(3).
doi: 10.1007/s10549-017-4358-6.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz 1 Oleg Gluz 2 Matthias Christgen 3 Ronald E Kates 1 Michael Clemens 4 Wolfram Malter 5 Benno Nuding 6 Bahriye Aktas 7 Sherko Kuemmel 8 Toralf Reimer 9 Andrea Stefek 10 Fatemeh Lorenz-Salehi 11 Petra Krabisch 12 Marianne Just 13 Doris Augustin 14 Cornelia Liedtke 1 Calvin Chao 15 Steven Shak 15 Rachel Wuerstlein 1 Hans H Kreipe 3 Nadia Harbeck 1 
Affiliations
  • PMID: 28664507
  •     29 References
  •     35 citations

Abstract

Background: The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating the prognostic value of RS, Ki-67, and other traditional clinicopathological parameters.

Methods: A central tumour bank was prospectively established within PlanB. Following an early amendment, hormone receptor (HR)+ , pN0-1 RS ≤ 11 patients were recommended to omit chemotherapy. Patients with RS ≥ 12, pN2-3, or HR-negative/HER2-negative disease were randomised to anthracycline-containing or anthracycline-free chemotherapy. Primary endpoint: disease-free survival (DFS). PlanB Clinicaltrials.gov identifier: NCT01049425.

Findings: From 2009 to 2011, PlanB enrolled 3198 patients (central tumour bank, n = 3073) with the median age of 56 years, 41.1% pN+, and 32.5% grade 3 EBC. Chemotherapy was omitted in 348/404 (86.1%) eligible RS ≤ 11 patients. After 55 months of median follow-up, five-year DFS in ET-treated RS ≤ 11 patients was 94% (in both pN0 and pN1) versus 94% (RS 12-25) and 84% (RS > 25) in chemotherapy-treated patients (p < 0.001); five-year overall survival (OS) was 99 versus 97% and 93%, respectively (p < 0.001). Nodal status, central/local grade, tumour size, continuous Ki-67, progesterone receptor (PR), IHC4, and RS were univariate prognostic factors for DFS. In a multivariate analysis including all univariate prognostic markers, only pN2-3, central and local grade 3, tumour size >2 cm, and RS, but not IHC4 or Ki-67 were independent adverse factors. If RS was excluded, IHC4 or both Ki-67 and PR entered the model. The impact of RS was particularly pronounced in patients with intermediate Ki-67 (>10%, <40%) tumours.

Interpretation: The excellent five-year outcomes in clinically high-risk, genomically low-risk (RS ≤ 11) pN0-1 patients without adjuvant chemotherapy support using RS with standardised pathology for treatment decisions in HR+ HER2-negative EBC. Ki-67 has the potential to support patient selection for genomic testing.

Keywords: Breast cancer; Genomic signature; IHC4; Ki-67; Oncotype DX.

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Reporting recommendations for tumor marker prognostic studies (REMARK).
Lisa M McShane, Douglas G Altman, +4 authors, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
J Natl Cancer Inst, 2005 Aug 18; 97(16). PMID: 16106022
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Giuseppe Viale, Meredith M Regan, +16 authors, International Breast Cancer Study Group.
J Natl Cancer Inst, 2008 Jan 31; 100(3). PMID: 18230798
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, +19 authors, International Ki-67 in Breast Cancer Working Group.
J Natl Cancer Inst, 2011 Oct 01; 103(22). PMID: 21960707    Free PMC article.
Highly Cited.
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.
Zsuzsanna Varga, Joachim Diebold, +16 authors, Hans-Anton Lehr.
PLoS One, 2012 Jun 05; 7(5). PMID: 22662150    Free PMC article.
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
Aleix Prat, Maggie Chon U Cheang, +8 authors, Charles M Perou.
J Clin Oncol, 2012 Dec 13; 31(2). PMID: 23233704    Free PMC article.
Highly Cited.
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
C Denkert, S Loibl, +17 authors, G von Minckwitz.
Ann Oncol, 2013 Aug 24; 24(11). PMID: 23970015
An international Ki67 reproducibility study.
Mei-Yin C Polley, Samuel C Y Leung, +16 authors, International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group.
J Natl Cancer Inst, 2013 Nov 10; 105(24). PMID: 24203987    Free PMC article.
Highly Cited.
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
M Gnant, M Filipits, +22 authors, Austrian Breast and Colorectal Cancer Study Group.
Ann Oncol, 2013 Dec 19; 25(2). PMID: 24347518
Highly Cited.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
Oleg Gluz, Ulrike A Nitz, +18 authors, Nadia Harbeck.
J Clin Oncol, 2016 Mar 02; 34(20). PMID: 26926676
Highly Cited.
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
R Wuerstlein, K Sotlar, +17 authors, N Harbeck.
Curr Med Res Opin, 2016 Mar 15; 32(7). PMID: 26971372
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
O Gluz, C Liedtke, +17 authors, N Harbeck.
Ann Oncol, 2016 Mar 30; 27(6). PMID: 27022068
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.
Torsten O Nielsen, Maj-Brit Jensen, +4 authors, Bent Ejlertsen.
Clin Cancer Res, 2016 Sep 08; 23(4). PMID: 27601592
Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
C Markopoulos, C van de Velde, +2 authors, R Masetti.
Eur J Surg Oncol, 2016 Sep 19; 43(5). PMID: 27639633
Review.
Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Megan C Roberts, Dave P Miller, Steven Shak, Valentina I Petkov.
Breast Cancer Res Treat, 2017 Mar 01; 163(2). PMID: 28243896
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.
Samuel C Y Leung, Torsten O Nielsen, +31 authors, Mitch Dowsett.
NPJ Breast Cancer, 2016 May 18; 2. PMID: 28721378    Free PMC article.
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies.
Angrit Stachs, Steffi Hartmann, Bernd Gerber.
Geburtshilfe Frauenheilkd, 2017 Aug 29; 77(8). PMID: 28845050    Free PMC article.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Frédérique Penault-Llorca, Thomas Filleron, +12 authors, Henri Roché.
BMC Cancer, 2018 May 08; 18(1). PMID: 29728098    Free PMC article.
Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer.
Hideo Shigematsu, Shinji Ozaki, +7 authors, Kiyomi Taniyama.
Oncotarget, 2018 Jun 22; 9(42). PMID: 29928479    Free PMC article.
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Danielle M Bello, Christy Russell, +2 authors, Monica Morrow.
Ann Surg Oncol, 2018 Jul 04; 25(10). PMID: 29968028    Free PMC article.
Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
Karin Beelen, Mark Opdam, +7 authors, Sabine Linn.
BMC Cancer, 2018 Jul 26; 18(1). PMID: 30041599    Free PMC article.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.
The Warwick Experience of the Oncotype DX® Breast Recurrence Score® Assay as a Predictor of Chemotherapy Administration.
Mashuk Alam Khan, Laura Henderson, +2 authors, Lucie Jones.
Breast Care (Basel), 2018 Dec 01; 13(5). PMID: 30498424    Free PMC article.
TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.
Joseph A Sparano, Robert Gray.
J Clin Oncol, 2019 Jun 08; 37(21). PMID: 31173552    Free PMC article.
21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.
Wei Wang, Lin Lin, +11 authors, Kunwei Shen.
Oncol Lett, 2019 Oct 04; 18(4). PMID: 31579428    Free PMC article.
Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Seho Park, Yunan Han, +7 authors, Yikyung Park.
Breast Cancer Res, 2019 Oct 18; 21(1). PMID: 31619259    Free PMC article.
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Salomon M Stemmer, Mariana Steiner, +16 authors, David B Geffen.
NPJ Breast Cancer, 2019 Nov 16; 5. PMID: 31728408    Free PMC article.
21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Yiwei Tong, Jiayi Wu, +6 authors, Kunwei Shen.
Sci Rep, 2019 Sep 13; 9(1). PMID: 31511599    Free PMC article.
Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
Kevin Kalinsky, Ruth M O'Regan.
Cancer, 2018 Nov 06; 125(2). PMID: 30387877    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score.
Weiqi Gao, Lin Lin, +2 authors, Kunwei Shen.
J Cancer, 2020 Mar 24; 11(9). PMID: 32201521    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.
Jill R Dietz, Meena S Moran, +16 authors, Katharine A Yao.
Breast Cancer Res Treat, 2020 Apr 26; 181(3). PMID: 32333293    Free PMC article.
Highly Cited.
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Cornelia Kolberg-Liedtke, Oleg Gluz, +13 authors, Nadia Harbeck.
Breast Cancer Res, 2020 May 16; 22(1). PMID: 32408905    Free PMC article.
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
K Almstedt, S Mendoza, +9 authors, M Schmidt.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436145    Free PMC article.
Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
Vincent P Walter, Florin-Andrei Taran, +6 authors, Andreas Daniel Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Jun 23; 80(6). PMID: 32565552    Free PMC article.
Adjuvant chemotherapy for node negative, high Recurrence ScoreTM breast cancer: in defense of de-escalation.
Diana Lake, Andrew D Seidman.
NPJ Breast Cancer, 2019 Aug 21; 5. PMID: 31428677    Free PMC article.
Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
Kai-Hua Liu, Lei Zhang, +4 authors, San-Gang Wu.
Breast, 2020 Jan 10; 49. PMID: 31918322    Free PMC article.
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.
Alberto Zambelli, Edda Simoncini, +11 authors, Carlo Tondini.
Breast, 2020 Apr 24; 52. PMID: 32325372    Free PMC article.
Luminal Breast Cancer: The Head of Janus in Breast Oncology.
Oleg Gluz.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982641    Free PMC article.
Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.
Aubriana M McEvoy, Steven Poplack, +7 authors, William E Gillanders.
Breast Cancer Res Treat, 2020 Jul 12; 183(2). PMID: 32651755    Free PMC article.
Review.
Landmark trials in the medical oncology management of early stage breast cancer.
Whitney Hensing, Cesar A Santa-Maria, Lindsay L Peterson, Jennifer Y Sheng.
Semin Oncol, 2020 Sep 17; 47(5). PMID: 32933761    Free PMC article.
Review.
The implementation of a commercially available multi-gene profile test for breast cancer characterization in a department of pathology: what have we learned from the first 100 cases?
Cristina Pelliccia, Emanuele Caselli, +3 authors, Angelo Sidoni.
Virchows Arch, 2021 Jan 07;. PMID: 33404851
Prognostic and predictive parameters in breast pathology: a pathologist's primer.
Kimberly H Allison.
Mod Pathol, 2020 Nov 07; 34(Suppl 1). PMID: 33154551
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Katya Losk, Rachel A Freedman, +7 authors, Tari A King.
Breast Cancer Res Treat, 2020 Sep 18; 185(1). PMID: 32939592
Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context.
Guillermo Arturo Valencia, Silvia Neciosup, +6 authors, Rodrigo Auqui.
World J Clin Oncol, 2021 Feb 09; 12(1). PMID: 33552937    Free PMC article.
The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
Roi Weiser, Waqar Haque, +4 authors, V Suzanne Klimberg.
Breast Cancer Res Treat, 2020 Oct 19; 185(3). PMID: 33070279
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer.
Della Makower, Juan Lin, Xiaonan Xue, Joseph A Sparano.
NPJ Breast Cancer, 2021 Mar 03; 7(1). PMID: 33649322    Free PMC article.
Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Serafin Morales Murillo, Ariadna Gasol Cudos, +6 authors, Antonieta Salud Salvia.
Breast, 2021 Feb 19; 56. PMID: 33601299    Free PMC article.
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Review.
How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients.
Xiaofu Zhu, Susan Dent, +5 authors, Xinni Song.
Curr Oncol, 2021 Feb 10; 28(1). PMID: 33557029    Free PMC article.